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Abstract
It is well known that RB functions are regulated by posttranslational modifications such as phosphorylation and
acetylation, but the significance of lysine methylation on RB has not been fully elucidated. Our expression analysis
of SMYD2 by quantitative real-time polymerase chain reaction showed that expression levels of SMYD2 are signif-
icantly elevated in human bladder carcinomas compared with nonneoplastic bladder tissues (P < .0001), and its
expression levels in tumor tissues were much higher than those of any other normal tissues. SMYD2 knockdown
resulted in the suppression of cancer cell growth, and cell cycle analysis indicated that SMYD2 might play a crucial
role in the G1/S transition. According to an in vitromethyltransferase assay, we found that SMYD2 methylates RB1
protein, and liquid chromatography–tandem mass spectrometry analysis revealed lysine 810 of RB1 to be methyl-
ated by SMYD2. Importantly, this methylation enhanced Ser 807/811 phosphorylation of RB1 both in vitro and
in vivo. Furthermore, we demonstrated that methylated RB1 accelerates E2F transcriptional activity and promotes
cell cycle progression. SMYD2 is an important oncoprotein in various types of cancer, and SMYD2-dependent RB1
methylation at lysine 810 promotes cell cycle progression of cancer cells. Further study may explore SMYD2-
dependent RB1 methylation as a potential therapeutic target in human cancer.
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Introduction
The retinoblastoma tumor suppressor protein (RB) has a central role
in cell cycle regulation and is mutated in several types of cancer [1–3].
RB can interact with the E2F transcription factor and regulate genes
related to S-phase entry. In its hypophosphorylated state RB binds to
E2F and repress the expression of E2F target genes. When RB is hyper-
phosphorylated by the Cyclin/CDK complexes, E2F is separated from
RB and transactivates its target genes that drive cell cycle progression
[1,2,4,5]. Although RB has been reported to be inactivated in more
than 90% of human small cell lung carcinomas [1], most human
cancers express wild-type RB that is predominantly at a phosphory-
lated state because of the deregulation of CDKs. Thereby, most human
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cancers seem to have lost the G1 checkpoint control through the dereg-
ulation of RB functions, and phosphorylation of RB is the key regula-
tory step in the pathway controlling proliferation of cancer cells [2]. In
addition to phosphorylation, RB protein has been known to be acety-
lated [6,7]. During keratinocyte differentiation, RB is acetylated by the
acetyltransferase P-CAF, and the acetylation of two major lysine resi-
dues (lysines 873 and 874) that are located within the nuclear localiza-
tion signal is likely to play a crucial role in differentiation through the
retention of the RB protein in the nucleus [8]. However, the signifi-
cance of other posttranslational modifications including lysine methyl-
ation for regulation of RB functions still remains unclear.
SMYD2 was first identified as one of the SMYD family members,
containing a SET domain and a MYND domain [9]. SMYD2
methylates H3K36 and functions as a transcriptional regulator in
cooperation with the Sin3A and HDAC1 histone deacetylase com-
plex [9]. Besides histone methylation process, SMYD2 also methy-
lates p53 and altering their functions [10]. In Xenopus laevis, smyd2
is expressed in muscle tissues and might be associated with muscle
cells differentiation [11]. In addition, Diehl et al. [12] showed that
Smyd2 is expressed in various types of neonatal mouse tissues and
particularly neonatal heart. However, Smyd2 is not critical for mouse
heart development, unlike Smyd1, which is indispensable for cardio-
myocyte differentiation and cardiac morphogenesis [13]. Thus,
although a part of biologic functions have been clarified, the roles
of SMYD2 in both nonneonatal cellular biology and diseases like
cancer remains largely unclear.
In this study, we show evidences that SMYD2 methylates lysine
810 of RB1, elevates phsophorylation level of RB, and promotes
the cell cycle progression. Our findings demonstrate a novel post-
translational modification of RB1, which may play a critical role in
human carcinogenesis.
Materials and Methods
Bladder Tissue Samples and RNA Preparation
Bladder tissue samples and RNA preparation were described pre-
viously [14–20]. Briefly, 125 surgical specimens of primary urothelial
carcinoma were collected, either at cystectomy or at transurethral
resection of bladder tumor (TURBT), and snap-frozen in liquid
nitrogen. Twenty-eight specimens of normal bladder urothelial tissue
were collected from areas of macroscopically normal bladder urothe-
lium in patients with no evidence of malignancy. Vimentin is pri-
marily expressed in mesenchymally derived cells, and it was used as
a stromal marker. Uroplakin is a marker of urothelial differentiation
and is preserved in up to 90% of epithelially derived tumors [21].
Use of tissues for this study was approved by Cambridgeshire Local
Research Ethics Committee (reference no. 03/018). RNA samples of
normal tissues (brain, breast, colon, esophagus, eye, heart, liver, lung,
pancreas, placenta, kidney, rectum, spleen, stomach and testis) were
purchased from BioChain (Newark, CA).
Cell Lines
CCD-18Co, HFL1, 5637, SW780, SCaBER, UMUC3, RT4, T24,
HT-1197,HT-1376, A549,H2170, SW480,HCT116, LoVo, COS7,
HeLa, and 293T cells were from the American Type Culture Collection
(Manassas, VA) in 2001 and 2003 and tested and authenticated byDNA
profiling for polymorphic short tandem repeat (STR) markers except
for SW780. The SW780 line was established in 1974 by A. Leibovitz
from a grade 1 transitional cell carcinoma. RERF-LC-AI and SBC5
cells were from the Japanese Collection of Research Bioresources
(Osaka, Japan) in 2001 and tested and authenticated by DNA profiling
for polymorphic STR markers. 253J, 253J-BV, and SNU-475 cells
were from the Korean Cell Line Bank (Seoul, Korea) in 2001 and tested
and authenticated by DNA profiling for polymorphic STR markers.
EJ28 cells were from Cell Lines Service (Eppelheim, Germany) in
2003 and tested and authenticated by DNA profiling for polymorphic
STR markers. ACC-LC-319 cells were from Aichi Cancer Center
(Nagoya, Japan) in 2003 and tested and authenticated by DNA profil-
ing for SNP, mutation, and deletion analysis.
All cell lines were grown in monolayers in appropriate media:
Dulbecco modified Eagle medium (DMEM) for EJ28, RERF-LC-
AI, COS-7, and 293T cells; Eagle minimum essential medium for
CCD-18Co, WI-38, 253J, 253J-BV, HT-1376, SCaBER, UMUC3,
HeLa and SBC5 cells; Leibovitz L-15 for SW480 and SW780 cells;
McCoy 5A medium for RT4, T24, and HCT116 cells; RPMI 1640
medium for 5637, A549, H2170, ACC-LC-319, and SNU-475 cells.
LoVo cells were cultured in Ham F-12 medium supplemented with
20% fetal bovine serum (FBS) and 1% antibiotic/antimycotic solution
(Sigma-Aldrich, St Louis, MO). All cells were maintained at 37°C in
humid air with 5% CO2 condition (SAEC, 5637, 253J, 253J-BV,
EJ28, HT-1197, HT-1376, J82, RT4, SCaBER, T24, UMUC3,
A549, H2170, ACC-LC-319, RERF-LC-AI, SBC5, and 293T cells)
or without CO2 (SW480 and SW780 cells). Cells were transfected with
FuGENE 6 (Roche Applied Science, Penzberg, Germany) according to
the manufacturer’s protocols.
Quantitative Real-time Polymerase Chain Reaction
As described above, we prepared 125 bladder cancer and 28 normal
bladder tissues in Addenbrooke’s Hospital, Cambridge. For quantita-
tive real-time polymerase chain reactions (RT-PCRs), specific primers
for all human GAPDH (housekeeping gene), SDH (housekeeping
gene), and SMYD2 were designed (primer sequences in Table W1).
PCRs were performed using the LightCycler 480 System (Roche
Applied Science) following the manufacturer’s protocol.
Immunohistochemical Staining
Paraffin-embedded tissue slides were purchased from BioChain.
Immunohistochemistry was performed using VECTASTAIN ABC
Reagent (PK-7100; Vector Laboratories, Burlingame, CA) and
DAB substrate kit for peroxidase (SK-4100; Vector Laboratories).
Slides of paraffin-embedded bladder tumor specimens and normal
human tissues were deparaffinized in xylene and followed by rehydration
in 99% ethanol. After wash by 1 × PBS (−), the slides were processed
under high pressure (125°C for 30 seconds) in an antigen retrieval solu-
tion, high pH 9 (S2367; Dako, Carpinteria, CA), and quenching was
performed by 0.3% hydrogen peroxide (H2O2) in methanol for 15 min-
utes. After blocking by 3% bovine serum albumin, tissue sections were
incubated overnight with a goat anti-SMYD2 polyclonal antibody
(sc-79084; Santa Cruz Biotechnology, Santa Cruz, CA) at a 1:250 dilu-
tion ratio, followed by reaction with an antigoat biotinylated IgG for
1 hour. After incubation with Vectastain ABC reagent, color develop-
ing was performed using DAB substrate kit for peroxidase. Finally, tis-
sue specimens were stained withMayer hematoxylin (Hematoxylin QS;
Vector Laboratories) to discriminate the nucleus from the cytoplasm.
Small interfering RNA Transfection
siRNA oligonucleotide duplexes were purchased from Sigma-
Aldrich for targeting the human SMYD2 transcripts. siNegative
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control (siNC), which is a mixture of three different oligonucleotide
duplexes, was used as control siRNAs.The siRNA sequences are described
in Table W2. siRNA duplexes (final concentration, 100 nM) were trans-
fected into bladder and lung cancer cell lines with Lipofectamine 2000
(Life Technologies, Carlsbad, CA) [17,22].
Clonogenicity Assays
COS-7 cells, cultured in DMEM 10% FBS, were transfected with
a p3×FLAG-Mock, p3×FLAG-SMYD2 wild-type (WT), or a
p3×FLAG-SMYD2 enzyme-dead mutant vector (ΔNHSC/ΔGEEV).
The transfected COS-7 cells were cultured for 2 days and seeded in a
10-cm dish at the density of 10,000 cells per 10-cm dish in triplicate.
Subsequently, the cells were cultured in DMEM 10% FBS containing
0.4 (mg/ml) Geneticin/G-418 for 2 weeks until colonies were visible.
Colonies were stained with Giemsa (Merck, Whitehouse Station, NJ)
and counted by Colony Counter software (Vector, Tokyo, Japan).
Mass Spectrometry
A protein band of SDS–polyacrylamide gel electrophoresis was
excised and reduced with dithiothreitol and carboxymethylated by
iodoacetic acid. After washing the gel, the band was digested with
Achromobacter Protease I (API, Lys-C a gift from Dr Masaki, Ibaraki
University) at 37°C overnight [23]. An aliquot of digest was analyzed by
nano liquid chromatography–tandem mass spectrometry (LC-MS/MS)
using LCQDeca XP plus (Thermo Fisher Scientific, San Jose, CA). The
peptides were separated using nano ESI spray column (100 μm [ID] ×
50 mm [L]) packed with a reversed-phase material (Inertsil ODS-3,
3 μm; GL Science, Tokyo, Japan) at a flow rate 200 nl/min. The mass
spectrometer was operated in the positive-ion mode, and the spectra
were acquired in a data-dependent MS/MS mode. The MS/MS spec-
tra were searched against the in-house database using local MASCOT
server (version 2.2.1; Matrix Sciences, London, United Kingdom).
The reduced and carboxylmethyated gel band was also digested with
endoproteinase Asp-N (Roche Applied Science) at 37°C overnight.
An aliquot of digest was deslated and applied to MALDI-TOF-MS
using an Ultraflex (Bruker Daltonik GmbH, Bremen, Germany). And
a selected peak was analyzed matrix-assisted laser desorption/ionization
tandem time-of-flight (MALDI-TOF/TOF) tandem mass spectrometry
in a LIFT mode.
Amino Acid Analysis
The excised protein bands blotted on the polyvinylidene fluoride
membranewere individually inserted in clean 6 × 32-mmglass tubes con-
taining 50 pmol of norvaline as internal standard and hydrolyzed in 6N
HCl vapor at 110°C for 20 hours. The hydrolyzed samples were deriv-
atized in situ by 6-aminoquinolyl-N -hydroxysuccinimidyl carbamate for
fluorophore detection. The 6-aminoquinolyl-N -hydroxysuccinimidyl
carbamate amino acids were separated by ion-pair chromatography
on a C18 reversed-phase column (Inertsil ODS-3, 4.6 mm [ID] ×
150 mm, 3 μm; GL Sciences, Tokyo, Japan). Both a laser-induced
fluorescence detector (LIF726; GL Sciences) and a fluorescence detec-
tor with Xe flush lamp (G1312A; Agilent Technologies, Santa Clara,
CA) were used to reveal the existence of monomethylated Lys [24].
Immunocytochemistry
Cells were fixed with PBS (−) containing 4% paraformaldehyde
for 30 minutes, and rendered permeable with PBS (−) containing
0.1% Triton X-100 at room temperature for 2 minutes. Subsequently,
the cells were covered with PBS (−) containing 3% bovine serum albu-
min for 1 hour at room temperature to block nonspecific hybridization
and were then incubated with rabbit anti-Rb (sc-102; Santa Cruz
Biotechnology), anti-p-Rb (Ser 807/811)-R (sc-16670-R; Santa Cruz
Biotechnology), goat anti-SMYD2 (sc-79084; Santa Cruz Biotechnol-
ogy), and mouse anti-FLAG (Sigma-Aldrich) at a 1:500 dilution ratio.
After washing with PBS (−), cells were stained by an Alexa Fluor 488–
conjugated antirabbit secondary antibody (Life Technologies) or an
Alexa Fluor 594–conjugated antimouse secondary antibody (Life Tech-
nologies) at a 1:500 dilution ratio. Nuclei were counterstained with
4′,6′-diamidine-2′-phenylindole dihydrochloride (DAPI). Fluorescent
images were obtained under a TCS SP2 AOBS microscope (Leica
Microsystems, Wetzlar, Germany).
Immunoprecipitation
293T cells were seeded at a density of 5 × 105 cells on a 100-mm
dish. The next day, the cells were transfected with expression vector
constructs using FuGENE 6 (Roche Applied Science) according to the
manufacturer’s recommendation. After 48 hours, transfected 293T
cells were washed with PBS and lysed in CelLytic M Cell Lysis Reagent
(Sigma-Aldrich) containing complete protease inhibitor cocktail
(Roche Applied Science). Five hundred micrograms of whole-cell ex-
tract was incubated with anti-FLAG M2 agarose (Sigma-Aldrich) for
1 hour at 4°C. After the beads were washed three times with 1 ml of
TBS buffer (pH 7.6), the FLAG-tagged proteins bound to the beads
were eluted by boiling in Lane Marker Sample Buffer (Thermo Fisher
Scientific, Hudson, NH). Samples were then subjected to SDS-PAGE
and detected by silver staining or Western blot.
Western Blot
Whole-cell lysates were prepared from the cells with RIPA-like
buffer or CelLytic M Cell Lysis Reagent (Sigma-Aldrich) containing
complete protease inhibitor cocktail (Roche Applied Science) and
total protein or immunoprecipitated samples were transferred to nitro-
cellulose membrane. The membrane was probed with anti-SMYD2
(sc-79084; Santa Cruz Biotechnology), anti-Rb (sc-102; Santa Cruz
Biotechnology), anti–phospho-Rb (Ser 807/811)-R (sc-16670-R;
Santa Cruz Biotechnology), anti–phospho-Rb (Ser 780) (C84F6;
Cell Signaling Technology, Danvers, MA), anti-ACTB (I-19, Santa
Cruz Biotechnology), anti-FLAG (Sigma-Aldrich), anti-HA (Santa
Cruz Biotechnology), and anti-His (631212; Clontech Laboratories,
Mountain View, CA) antibodies. An anti–mono-methylated RB1
K810 antibody was made by Sigma-Aldrich. Protein bands were
detected by MemCode Reversible Protein Stain Kit (24580; Thermo
Fisher Scientific).
In Vitro Methyltransferase Assay
For the in vitro methylation assay, His-WT-RB1, His-K810A-RB1,
and His-SMYD2 were used as described previously. One microgram of
RB1 was incubated with 1 μg of SMYD2 in 1.0 M Tris-HCl (pH 8.8),
1.0 μCi/ml S -adenosyl-L-[methyl-3H] methionine (SAM; Perkin
Elmer, Waltham, MA) and Milli-Q water for 1 hour at 30°C. After
boiling in sample buffer, the samples were subjected to SDS-PAGE,
followed by visualization by fluorography [25].
In Vitro Kinase Assay
CDK4/CyclinD1 (ab55695; Abcam,Cambridge, UnitedKingdom)
was used for kinase assay in a reaction buffer containing 40mMMOPS
(pH 7.0), 1mMEDTA, and 20mMATP for 10minutes at 30°C. After
boiling in sample buffer, the samples were subjected to SDS-PAGE.
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Results
SMYD2 Is Overexpressed in Human Cancer and Regulates the
Growth of Cancer Cells
We examined expression levels of genes belonging to the histone
methyltransferase family in clinical bladder samples and found a sig-
nificant increase in the SMYD2 expression compared with normal
bladder epithelial cells. Then we analyzed 125 bladder cancer sam-
ples and 28 normal control samples (British) and confirmed signifi-
cant elevation of SMYD2 expression in tumor cells (P < .0001,
Mann-Whitney U test) (Figure 1A and Table 1, patient characteris-
tics). We also compared the expression levels of SMYD2 between
bladder tumor and various types of normal tissues and found that
the expression of SMYD2 in bladder tumor tissues is significantly
higher than those in normal tissues, including the heart, the lung,
the liver, and the kidney (Figure 1B). Immunohistochemical analysis
using an anti-SMYD2 antibody confirmed overexpression of SMYD2
at the protein level in bladder cancer tissue sections (Figure 1C ).
Figure 1. SMYD2 is overexpressed in cancer tissues and involved in the growth of cancer cells. (A) Expression analysis of SMYD2 at mRNA
levels in 125 bladder cancer cases and 28 normal bladder cases by quantitative RT-PCR, and results are shown by box-whisker plot. GAPDH
and SDH were used as housekeeping genes. Mann-Whitney U test was used for statistical analysis (P < .0001). (B) Comparison of mRNA
levels of SMYD2 between bladder cancer samples and normal organ tissues. The normal organ tissues include brain, breast, colon, esoph-
agus, eye, heart, liver, lung, pancreas, placenta, kidney, rectum, spleen, stomach, and testis. (C) Immunohistochemical analysis of bladder
cancer and normal bladder tissues. All tissue samples were purchased from BioChain. Original magnification, ×200. (D) Validation of
SMYD2 knockdown at the protein level. Lysates from SW780 and RT4 cells 72 hours after siRNA treatment were immunoblotted with
anti-SMYD2 and anti-ACTB (an internal control) antibodies. (E) Effects of SMYD2 knockdown on the proliferation of bladder cancer cell lines
(SW780 and RT4) measured by Cell Counting Kit-8. Relative cell numbers are normalized to the number of siNC-treated cells (siNC = 1):
results are the mean ± SD (error bars) of three independent experiments. P values were calculated using Student’s t test (*, P < .05).
(F) Methylation activity of SMYD2 is critical for its growth-promoting effect. COS-7 cells were transfected with FLAG-Mock, -SMYD2 (WT
or ΔNHSC/ΔGEEV) and, 10 days after transfection, were stained with Giemsa. Expression of SMYD2 (WT or ΔNHSC/ΔGEEV) was confirmed
by Western blot using anti-FLAG antibody. Expression of ACTB served as a control.
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Furthermore, the Oncomine database records that SMYD2 is over-
expressed in various types of human cancer: colon, prostate, and
breast cancer (Figure W1). These results indicate that expression
levels of SMYD2 are widely elevated in human cancer.
To investigate whether SMYD2 is indispensable for cancer cell via-
bility, we first examined expression levels of SMYD2 in cell lines and
found overexpression of SMYD2 in bladder, lung, colon, and liver
cancer cell lines compared with the normal fibroblast cell line WI-38
(Figure W2). We then suppressed the SMYD2 expression in bladder
cancer cells (SW780 and RT4) using two independent siRNAs. After
confirming knockdown by those siRNAs (Figure 1D), we performed
cell growth assays and found significant growth suppression of the cells
treated with SMYD2 siRNAs compared with control siRNA (siNC;
Figure 1E ). Significant growth suppression was also observed when
we used lung cancer cell lines (A549, ACC-LC-319, and SBC5;
Figure W3). To examine oncogenic activity of SMYD2, we conducted
a clonogenicity assay. We transfected either a wild-type SMYD2
(SMYD2 WT) vector, an enzyme-dead SMYD2 (SMYD2 ΔNHSC/
ΔGEEV) vector, or a mock vector into COS-7 cells and performed a
clonogenicity assay (Figure 1F). The cells transfected with a wild-type
SMYD2 vector were found to form more colonies than those trans-
fected with an enzyme-dead SMYD2 vector or a mock control vector,
implying the importance of the methylation activity of SMYD2 in its
oncogenic activity. Because overexpression of SMYD2 was observed in
an early-stage cancer, SMYD2 may play a crucial role in an early step
of carcinogenesis.
To further elucidate the biologic effects of SMYD2 on the growth
of cancer cells, we introduced a SMYD2 expression vector containing
the Flp-In T-REx system (T-REx-293; Life Technologies) into human
embryonic kidney fibroblast (HEK293) cells. We transfected either a
V5-tagged SMYD2 expression vector (SMYD2), an empty vector
(Control), or a V5-tagged CAT expression vector (CAT) into T-REx-
293 cells and then established cell lines overexpressing SMYD2. We
analyzed cell cycle status by FACS analysis (Figure W4A) and found
that the proportion of cells in the S phase in those overexpressing
SMYD2 was significantly increased compared with control (P < .01)
or CAT (P < .05). Concordantly, the proportion of cells in the G0/G1
phase in those overexpressing SMYD2was slightly lower than in the two
control cells (P < .01 [Mock, SMYD2] and P < .01 [CAT, SMYD2],
respectively). We also performed BrdU and 7-amino-actinomycin D
staining to analyze the detailed cell cycle status of cancer cells and con-
firmed that the proportion of cancer cells at the S phase was significantly
decreased after the knockdown of SMYD2 (Figure W4B ).
SMYD2 Methylates Lysine 810 of RB1 Both
In Vitro and In Vivo
To identify a critical substrate of SMYD2 involved in human carcino-
genesis, we performed an in vitro methyltransferase assay using various
tumor-related proteins as substrates and found a strong methylation
signal when we used RB1 protein as a substrate (Figure 2A). To further
verify the interaction between RB1 and SMYD2 proteins, we carried
out a coimmunoprecipitation assay after cotransfection of FLAG-
SMYD2 andHA-RB1 or FLAG-RB1 andHA-SMYD2 expression vec-
tors into 293T cells and confirmed their bindings (Figure 2, B and C ).
In addition, an immunoprecipitation assay using deletion mutants of
SMYD2 showed that the C-terminal portion of SMYD2 is essential
to interact with RB1 (Figure 2D). Furthermore, we also confirmed
the colocalization of endogenous RB1 and SMYD2 proteins in the
small cell lung cancer cell line SBC5 by immunocytochemical analysis
(Figure 2E ).
We next constructed plasmid vectors that were designed to express
parts of RB1 protein to identify a methylation site of RB1 by SMYD2
and prepared recombinant proteins expressed in Escherichia coli. Using
those proteins, we conducted an in vitro methyltransferase assay
(Figure 3A) and found that the C-terminal region (773 aa to 928 aa) of
RB1 protein includes the methylation site(s). Subsequent LC-MS/MS
analysis indicated lysine 810 on RB1 to be monomethylated by
SMYD2 (Figure 3B). The SMYD2-dependent lysine monomethylation
was also confirmed by amino acid analysis (Figure W5). To validate the
methylation site of RB1 we identified, we prepared a partial RB1 pro-
tein, which was replaced lysine 810 to alanine (K810A-RB1 (773-813))
and performed an in vitromethyltransferase assay (Figure 3C ). The spe-
cific methylation signal of the wild-type RB1 protein by SMYD2 was by
the replacement of K810. On the basis of these results, we generated a
polyclonal antibody targeting K810-monomethylated RB1 peptide. To
validate the specificity of the antibody, we performed an in vitro
methyltransferase assay with or without SMYD2 and observed a
SMYD2-dependent methylation signal (Figure 3D). We also found
that this antibody could recognize neither the K810-substituted RB1
protein treated with wild-type SMYD2 in vitro (Figure 3E ) nor the
wild-type RB1 protein treated with enzyme-dead SMYD2 in vivo
(Figure 3F ). These results imply that SMYD2 methylates lysine 810
of RB1 protein both in vitro and in vivo, and the antibody we generated
can specifically recognize K810-methylated RB1.
SMYD2 Enhances Phosphorylation of RB1 at Ser 807/811
through Methylation of Lys 810
As it is well known that phosphorylation plays a crucial role in the
regulation of RB1 functions [3,5], we examine the effect of Lys 810
methylation on the phosphorylation status of RB1. We first performed
Western blot analysis of two noncancerous cell lines and seven cancer
cell lines to examine the phosphorylation status of RB1 at Ser 807/811
and found some correlation between the higher phosphorylation sta-
tus of RB1 and high SMYD2 expression (Figure 4A). To clarify
whether SMYD2 affects RB1 phosphorylation status through methyl-
ation of Lys 810, we conducted gain-of-function and loss-of-function
Table 1. Statistical Analysis of SMYD2 Expression Levels in Clinical Bladder Tissues.
Characteristic n SMYD2
Mean SD 95% CI
Normal (control) 28 1.055 0.512 0.866-1.245
Tumor (total) 125 7.092 10.474 5.256-8.929
Tumor grade
1 12 6.879 4.391 4.395-9.363
2 63 8.633 13.833 5.217-12.049
3 49 5.195 5.001 3.794-6.595
Metastasis
Negative 98 7.442 11.551 5.155-9.729
Positive 27 5.823 4.831 4.001-7.646
Sex
Male 91 6.623 8.600 4.856-8.390
Female 32 5.210 5.120 3.436-6.984
Recurrence
No 28 9.221 13.198 4.332-14.110
Yes 51 5.541 5.465 4.041-7.041
Died 8 5.539 6.733 0.873-10.205
Smoke
No 27 5.882 4.601 4.147-7.618
Yes 49 7.476 11.231 4.331-10.620
CI indicates confidence interval.
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experiments. After introduction of FLAG-SMYD2 into 293T cells,
we detected a significant elevation of phosphorylation status of RB1
at Ser 807/811 compared with the cells transfected with a mock vector
(Figure 4B). Subsequent immunocytochemical analysis detected that
overexpression of WT-SMYD2 enhanced phosphorylation of RB1 at
Ser 807/811 inHeLa cells (Figure 4C). Concordantly, phosphorylation
of RB1 at Ser 807/811 was significantly reduced after knockdown of
SMYD2 (Figure 4D). To examine the effect of methyltransferase activ-
ity of SMYD2 on phosphorylation status of RB1, we transfected a vec-
tor designed to express a partial RB1 (FLAG-RB1(773-813)) together
with a wild-type SMYD2 expression vector (HA-SMYD2) or with an
enzyme-dead SMYD2 expression vector (HA-SMYD2 (ΔNHSC/
GEEV)) into 293T cells, and conducted immunoprecipitation using
anti-FLAG M2 agarose. As shown in Figure 4E , the phosphorylation
level of RB1 at Ser 807/811 in the cells transfected with WT-SMYD2
was significantly higher than that in the cells with enzyme-dead
SMYD2. Hence, SMYD2-dependent RB1 methylation seems to en-
hance phosphorylation status of RB1 at Ser 807/811.
To evaluate the effect of SMYD2-dependent methylation on the
phosphorylation status of RB1, we performed an in vitro kinase assay
using RB1 as a substrate reacted with or without SMYD2 (Figure 5A).
After confirmation of Lys 810 methylation of RB1 (Figure 5B, top),
we reacted the samples with the CDK4/Cyclin D1 complex, which is
an important regulator of RB1 phosphorylation, and monitored phos-
phorylation status of RB1 at Ser 807/811 byWestern blot (Figure 5B,
bottom). Importantly, methylated RB1 showed higher phosphoryla-
tion levels than nonmethylated protein. In addition, when we examined
the dose-dependent effect of SMYD2 on the RB1 phosphorylation at
Ser 807/811, it was increased in a dose-dependent manner, correlating
with methylation levels of RB1 at Lys 810 (Figure 5C ). Likewise,
Figure 2. SMYD2 methylates RB1 and makes a complex through its C-terminal domain. (A) RB1 is methylated by SMYD2. In vitromethyl-
transferase reaction was performed using purified N-RAS, H-RAS, K-RAS, RB1, p53, Aurora B, and AKT1 recombinant proteins. Meth-
ylated proteins were visualized with fluorography. (B and C) Coimmunoprecipitation assays of SMYD2 and RB1 proteins. 293T cells were
cotransfected with a SMYD2 expression vector and a RB1 expression vector or a mock control vector. The interaction of FLAG-SMYD2
and HA-RB1 (B) or FLAG-RB1 and HA-SMYD2 (C) was examined by immunoprecipitation using anti-FLAG M2 agarose and immuno-
blotted with anti-FLAG and anti-HA antibodies. (D) The C-terminal region of SMYD2 is essential for the interaction with RB1. 293T cells
were cotransfected with a FLAG-RB1 expression vector and three different regions of HA-SMYD2 vectors (amino acids 1-250, 250-330,
and 320-433 in SMYD2 protein). Immunoprecipitation was performed using HA-Agarose, and samples were immunoblotted with anti-
FLAG and -HA antibodies. (E) Colocalization of SMYD2 and RB1 proteins in SBC5 cells. SBC5 cells were stained with anti-RB1 (Alexa
Fluor 488 [green]) and anti-SMYD2 (Alexa Fluor 594 [red]) antibodies, and DAPI [blue]). Scale bar, 30 μm.
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mutant RB1 containing a substitution of Lys 810 to alanine showed
much weaker phosphorylation levels than wild-type RB1 (Figure 5D),
implying that methylation of RB1 at Lys 810 seems to enhance phos-
phorylation levels of RB1. We then prepared a K810 monomethylated
RB1 peptide (K810me-RB1 peptide) and a K810 unmethylated RB1
peptide (Control-RB1 peptide) and investigated the effect of K810
monomethylation on the phosphorylation of RB1 at Ser 807/811 by
the CDK4/Cyclin D1 complex in more detail (Figure 5E ). After
confirmation of K810 monomethylation by dot blot analysis using an
anti-RB1 K810me antibody, we conducted a kinase assay and found
significantly higher phosphorylation levels of RB1 at Ser 807/811 in
the K810me-RB1 peptide than in the unmethylated peptides
(Figure 5F). The CDK4 dose-dependent elevation of RB1 phosphoryla-
tion at Ser 807/811 in the K810me-RB1was also confirmed (Figure 5G).
These findings indicate that K810monomethylation of RB1 by SMYD2
can enhance the phosphorylation level of RB1 at Ser 807/811.
Lys 810 Methylation of RB1 Promotes Cell Cycle Progression
To further evaluate the effect of methylation on phosphorylation
status of RB1 in vivo, we transfected a FLAG-WT-RB1 vector or a
FLAG-K810A-RB1 vector with a HA-WT-SMYD2 vector into
293T cells and carried out immunoprecipitation with anti-FLAG
M2 agarose (Figure 6A). Consistent with previous data, WT-RB1
showed higher phosphorylation levels of RB1 at Ser 807/811 than
Lys 810–substituted RB1 (K810A-RB1), and this result was also con-
firmed using a partial RB1 (773-813) (Figure 6B). Taken together,
methylation of RB1 at Lys 810 also seems to enhance the phosphory-
lation status of RB1 in vivo.
It is known that CDK-mediated phosphorylation of RB1 prevents
the interaction of RB1 with E2F1, a multifunctional transcription
factor that activates the genes required for the cell cycle progression at
the G1/S transition and enables E2F1-dependent gene expression [5].
Because Lys 810 methylation enhanced the phosphorylation of RB1,
Figure 3. SMYD2 methylates RB1 at K810. (A) The C-terminal region of RB1 is methylated by SMYD2. In vitro methyltransferase assay
was performed using purified RB1 recombinant proteins (RB1 (Full), RB1 (1-378), RB1 (379-928), and RB1 (773-928)), and methylated
proteins were visualized with fluorography. (B) MS/MS spectrum of monomethyl peptide of RB1. RB1 protein (773-928) was treated with
SMYD2 and then the mixture was subjected to SDS-PAGE. After CBB staining, a protein band of ∼25 kDa was digested with API and
subjected to LC-MS/MS. A spectrum for the monomethylated RB1 is shown. The *K indicates monomethyl lysine. (C) K810A-RB1 is not
methylated by SMYD2. In vitro methyltransferase assay was performed using RB1 (773-928, 773-813), K810A-RB1 (773-813). (D and E)
Validation of the anti-K810me RB1 antibody. In vitro methyltransferase assay was conducted with RB1 (Full) and RB1 (773-928) (D) or
RB1 (773-813) and K810A-RB1 (773-813) (E). The samples were immunoblotted with anti-RB1K810me and anti-His (internal control) anti-
bodies. (F) 293T cells were cotransfected with a FLAG-WT-RB1 vector or a FLAG-K810A-RB1 vector and an HA-WT-SMYD2 vector or an
HA-SMYD2 (ΔNHSC/GEEV) vector. Immunoprecipitation was performed using anti-FLAG M2 agarose, and the samples were immuno-
blotted with anti-RB1K810me, anti-FLAG, and anti-HA antibodies.
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we performed an E2F reporter assay to examine the effect of RB1meth-
ylation on the cell cycle. E2F-luciferase activity was significantly low in
the cells overexpressing Lys 810-substituted RB1 compared with the
cells overexpressing wild-type RB1 (Figure 6C ). This result indicated
that Lys 810 methylation of RB1 might promote E2F transcriptional
activity in vivo. Furthermore, we established stable cell lines, which can
express wild-type RB1 (WT) and K810-substituted RB1 (K810A) by
induction of doxycycline, using Flp-In T-REx 293 cell line system.
Consistent with our data, cells expressing wild-type RB1 showed higher
cell growth rate than cells expressing RB1 (K810A; Figure W6). Taken
together, Lys 810 methylation of RB1 by SMYD2 seems to promote
cell cycle progression through an increase in RB1 phosphorylation.
Discussion
The RB1 gene, a member of the pocket family with p107 and p130,
was the first known tumor suppressor [26,27]. The RB protein
mainly functions as a transcriptional cofactor that can regulate nu-
merous transcriptional factors and affect the expression of a large
number of target genes. In addition, it is well known that the RB1
protein is targeted by the transforming proteins of the DNA tumor
viruses like adenoviral E1A and is functionally inactivated in most
human tumor cells owing to mutations of either the RB1 gene itself
or its upstream regulators [28]. Its tumor suppressive activity is largely
dependent on its ability to directly bind to members of the E2F tran-
scriptional family and prevent them from promoting transcription of
genes required for cell proliferation [28]. Researchers have paid atten-
tion to the RB/E2F pathway because it is often altered in cancer cells
and deregulates the cell proliferation control system [29]. With regard
to the cell proliferation regulation, mitogens reverse transcriptional
inhibition of E2F-dependent promoters through sequential activation
of CDK-cyclin complexes, which phosphorylate RB and attenuate its
transcriptional corepressor capability [2,30,31]. This phosphorylation
Figure 4. SMYD2 enhances RB1 phosphorylation. (A) Expression levels of SMYD2 correlate with phosphorylation levels of RB1 (Ser 807/811).
Lysates from normal cell lines (CCD18Co and HFL1) and cancer cell lines (HeLa, ACC-LC-319, A549, SW480, SW780, HCT116, and SBC5)
were immunoblottedwith anti–phospho-RB1 (Ser 807/811), anti-SMYD2, and anti-ACTB (internal control) antibodies. (B) 293T cells were trans-
fectedwith a FLAG-SMYD2 vector and amock vector (negative control). Cells were lysedwith RIPA-like buffer containing complete protease
inhibitor cocktail, and samples were immunoblotted with anti-FLAG, anti–phospho-RB1 (Ser 807/811), and anti-RB1 (internal control) anti-
bodies. (C) After transfection with an HA-SMYD2 vector into HeLa cells, cells were fixed with 4% paraformaldehyde (PFA) and permeabilized
with 0.5% Triton X-100. The fixed cells were stained with anti–phospho-RB1 (Ser 807/811) (Alexa Fluor 488 [green]) and anti-HA (Alexa Fluor 594
[red]) antibodies, and DAPI (blue). (D) Knockdown of SMYD2 diminishes phosphorylation levels of RB1 (Ser 807/811). After knockdown of
SMYD2 using SMYD2-specific siRNAs, cells were lysed with RIPA-like buffer containing complete protease inhibitor cocktail. Immunoblot
was performedwith anti-SMYD2, anti–phospho-RB1 (Ser 807/811), and anti-RB1 (internal control) antibodies. (E) 293T cells were transfected
with a FLAG-RB1 (773-813) vector and an HA-WT-SMYD2 vector and an HA-SMYD2 (ΔNHSC/GEEV) vector. Immunoprecipitation was con-
ducted with anti-FLAGM2 agarose. Anti-FLAG, anti–phospho-RB1 (Ser 807/811), and anti–phospho-RB1 (Ser 780) antibodies were used for
immunoblot analysis.
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is sufficient to induce RB protein to release E2F, and subsequently
induce the E2F-responsive genes at the late G1 phase. Importantly,
most human tumors carry mutations that disable RB protein-mediated
repression of E2F [5]. These mutations either inactivate the RB1 gene
itself or promote phosphorylation of RB protein in the absence of
normal mitogenic signal through activation of the cyclin D–CDK4/6
kinases or inactivation of the CDK inhibitor p16. These alterations
result in the inappropriate release of E2F, thereby inducing transcrip-
tional activation of E2F target genes and, consequently, enhancing cell
proliferation in cancer cells [27]. In this study, we found that Lys 810 of
RB1 is monomethylated by SMYD2, which promotes cell cycle pro-
gression through elevation of RB1 phosphorylation and E2F1 tran-
scriptional activity (Figure 6D). This result adds new insight in the
deregulation mechanism of the RB/E2F pathway in human cancer
cells. Intriguingly, most recently, other groups also identified lysine
methylation on RB protein [32,33]. Taken together, lysine methylation
is likely to play a critical role in the regulation of RB functions, and
further functional analyses may totally unveil the importance of lysine
methylation in the RB/E2F pathway.
We previously showed that some histone methyltransferases
(HMTs) play vital roles in human cancer pathogenesis [22,34–36].
Other groups have also proposed involvement of HMTs in malignant
alterations of human cells [37–39]. These kinds of evidence clearly
indicate that deregulation of HMTs makes a significant contribution
to human carcinogenesis, but the detailed molecular mechanisms of
HMTs abnormality in human carcinogenesis still remains to be
Figure 5. SMYD2-dependent monomethylation of RB1 at Lys 810 increases the phosphorylation of RB1 at Ser 807/811 in vitro. (A) Research
strategy of sequential in vitro methylation and kinase assays. (B) In vitro methyltransferase assay was performed using recombinant RB1
(773-813) protein as a substrate reacted with bovine serum albumin (negative control) or SMYD2 as an enzyme. After confirmation of RB1
methylation by Western blot with anti-RB1K810me antibody, in vitro kinase assay was conducted using CDK4/Cyclin D1 complex as an
enzyme. The samples were immunoblotted with an anti–phospho-RB1 (Ser 807/811) antibody. Amounts of loading proteins were visualized
byMemCode Reversible Protein Stain (Thermo Fisher Scientific). (C) Methylation of RB1 at Lys 810 enhances phosphorelation levels of RB1
(Ser 807/811). After in vitro methyltransfease assay of RB1 treated with several different doses of SMYD2, in vitro kinase assay was per-
formed with CDK4/Cyclin D1 complex as an enzyme. The samples were immunoblotted with anti–phopspho-RB1 (Ser 807/811) and anti-RB1
K810me antibodies. Amounts of loading proteins were visualized byMemCode Reversible Protein Stain (Thermo Fisher Scientific). (D) In vitro
methyltransferase and kinase assays with WT-RB1 (773-813) and K810A-RB1 (773-813). Anti–RB1 K810me, anti–phospho-RB1 (Ser 807/811),
and anti-His (internal control) antibodies were used for the immunoblot analysis. (E) Sequences of methylated and unmethylated peptides of
RB1. (F) In vitro kinase assay of K810 methylated or unmethylated RB1 peptides was performed with CDK4/Cyclin D1 as an enzyme source.
Anti-RB1 K810me and anti–phospho-RB1 (Ser 807/811) antibodies were used for immunoblot analysis. Amounts of loading peptides were
visualized byMemCode Reversible Protein Stain (Thermo Fisher Scientific). Mean± SD (error bars) of two independent experiments. P values
were calculated using Student’s t test (**P < .01). (G) In vitro kinase assay of RB1 peptides treated with two different doses of CDK4/Cyclin
D1. Amounts of loading peptides were visualized by MemCode Reversible Protein Stain (Thermo Fisher Scientific).
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clarified. In this study, we demonstrated that SMYD2 is overexpressed
in various cancer tissues and that SMYD2 methylates RB1 as a sub-
strate. Although some novel targets have been identified and newly
emerging anticancer drugs are under clinical trials, current chemother-
apy fails to ensure satisfying outcomes, and adverse events are still not
negligible [40,41]. Therefore, it is crucial to identify ideal therapeutic
targets to improve the efficacy and decrease the adverse effects for pro-
viding the better quality lives to cancer patients. According to our
study, SMYD2 plays a crucial role in human carcinogenesis. Impor-
tantly, Komatsu et al. [42] recently revealed that overexpression of
SMYD2 protein was frequently detected in primary tumor samples
of esophageal squamous cell carcinoma, and patients with SMYD2-
overexpressing tumors had worse overall rate of survival than those with
nonexpressing tumors. In addition, SMYD2 positivity was indepen-
dently associated with a worse outcome in the multivariate analysis
[42]. Taken together, considering that methodologies to generate
HMTs inhibitors have recently been developed [43,44], SMYD2 is
likely to be an ideal therapeutic target in cancer, with fewer adverse
events because of its low expression in normal cells. Further study
may reinforce the importance of SMYD2 as a target of cancer therapy,
and the development of a SMYD2 specific inhibitor seems to be one
of the promising strategies of cancer therapy.
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Table W1. Primer Sequences for Quantitative RT-PCR.
Gene Name Primer Sequence
GAPDH (housekeeping gene) GAPDH-f GCAAATTCCATGGCACCGTC
GAPDH-r TCGCCCCACTTGATTTTGG
SDH (housekeeping gene) SDH-f TGGGAACAAGAGGGCATCTG
SDH-r CCACCACTGCATCAAATTCATG
SMYD2 SMYD2-f ATCTCCTGTACCCAACGGAAG
SMYD2-r CACCTTGGCCTTATCCTTGTCC
Table W2. siRNA Sequences.
siRNA Name Sequence
siEGFP Sense GCAGCACGACUUCUUCAAG
Antisense CUUGAAGAAGUCGUGCUGC
siNegative control (cocktail)
Target no. 1 Sense AUCCGCGCGAUAGUACGUA
Antisense UACGUACUAUCGCGCGGAU
Target no. 2 Sense UUACGCGUAGCGUAAUACG
Antisense CGUAUUACGCUACGCGUAA
Target no. 3 Sense UAUUCGCGCGUAUAGCGGU
Antisense ACCGCUAUACGCGCGAAUA
siSMYD2 no. 1 Sense GAUUUGAUUCAGAGUGACA
Antisense UGUCACUCUGAAUCAAAUC
siSMYD2 no. 2 Sense GAAUGACCGGUUAAGAGA
Antisense UCUCUUAACCGGUCAUUUC
Figure W1. SMYD2 is overexpressed in various types of cancer. Gene expression data in Oncomine was analyzed. The thick bars in the
boxes are average expression levels, and the boxes represent 95% of the samples. The error bars are above or below the boxes, and the
range of expression levels is enclosed by two dots.
Figure W2. Quantitative RT-PCR analysis was performed to ex-
amine expression levels of SMYD2 at the mRNA level in two non-
cancerous cell lines (WI-38 and IMR-90), 14 bladder cancer cell
lines (SW780, J82, RT4, UMUC3, HT-1197, HT-1376, 5637, EJ28,
T24, 253J, 253JBV, and SCaBER), 5 lung cancer cell lines (RERF-
LC-AI, ACC-LC-319, H2170, A549, and SBC5), 2 colon cancer cell
lines (LoVo and HCT116), and 1 liver cancer cell line (SNU475).
Figure W3. Effects of SMYD2 knockdown on the proliferation of
lung cancer cell lines. Relative cell numbers are measured by Cell
Counting Kit-8 and normalized to the number of siNC-treated cells
(siNC = 1): results are the mean ± SD (error bars) of three inde-
pendent experiments. P values were calculated using Student’s
t test (*P < .05).
Figure W4. SMYD2 promotes the G1/S transition of cell cycle. (A) Numerical analysis of the FACS result, classifying cells by cell cycle status.
The proportion of T-REx-SMYD2 cells in S phases is slightly higher than control cells (T-REx-Mock and T-REx-CAT). Mean ± SD (error bars)
of three independent experiments. Fisher Protected least significant difference post hoc test was used to calculate P values (**P< .01, *P<
.05). (B) Cell cycle distribution was analyzed by flow cytometry after coupled staining with fluorescein isothiocyanate–conjugated anti-BrdU
and 7-amino-actinomycin D as described in Materials and Methods.
Figure W5. Chromatogram of amino acids obtained by acid hydrolysis of RB1 after treatment with SMYD2 (red line) or without SMYD2
(blue line). Inserted figure shows a magnified view of the region around the arginine. Except for monomethylated lysine (MK) and norvaline
(n-V), amino acid residues are annotated using their one-letter abbreviations. AMQ indicates 6-amino quinoline derived from hydrolysis of the
derivatizing reagent for amino acids; NH3, ammonia.
Figure W6. Cell growth analysis of Flp-In T-REx 293 cell lines. We
established stable cell lines, which can overexpress wild-type RB1
(RB1-WT) and K810-substituted RB1 (RB1-K810A), using Flp-IN T-REx
system (Life Technologies). Bothwild-type and K810-substituted RB1
proteins were induced by 1 μg/ml doxycycline. The number of cells
were calculated by Cell Counting Kit-8 (Dojindo, Kumamoto, Japan),
and the y value shows the relative cell number to day 1 (d1 = 1).
